OHSU patient Darrah Isaacson shares her experience with the long-term impacts of COVID-19 during a press conference with Gov. Kate Brown. She says: “It’s exhausting to be vigilant about keeping your distance, wearing your mask, sanitizing your hands or even your groceries, but I am here to tell you that the alternative is way more exhausting.”

Across all Oregon industries, OHSU is the fourth most admired company, behind Nike, Columbia Sportswear and Intel.

OHSU is Oregon’s most admired health care company, according to Portland Business Journal’s annual ranking; OHSU Doernbecher (#7) and OHSU Knight Cancer Institute (#11) are also recognized.

Mark Slifka, Ph.D., explains the FDA emergency authorization for the first COVID vaccine, and says “The vaccine is looking safe and it’s looking effective. Now is the time to start using it.”

OHSU Doernbecher medical assistant, and pediatric cancer survivor, Jordan Herrle becomes the youngest member of Camp Ukandu’s leadership team.

Katharine Zuckerman, M.D., M.P.H., offers advice about raising a child with autism or developmental delays.

Kevin Winthrop, M.D., M.P.H., is featured in a Spero Therapeutics press release announcing the inaugural dosing of patients with nontuberculous mycobacterial pulmonary disease with an antimicrobial agent as a part of a Phase 2a clinical trial. Winthrop says: “Oral SPR720 shows potential to benefit patients with NTM pulmonary disease and we are excited to have initiated this novel Phase 2a trial to assess SPR720 in patients with early onset pulmonary disease.”

In a Health Central slideshow on recurrence of melanoma following surgery, Sancy Leachman, M.D., Ph.D., says “If you’ve got a little bit of spread, we know your risk of spread elsewhere is high.”

OHSU’s work to provide the first CRISPR gene editing procedure within the human body to treat an inherited cause of blindness was named the No. 3 top scientific discovery of 2020.

Research conducted by Jane Zhu, M.D., M.P.P. is included in a feature about gender inequality in America.